Retinoid Agonist Drug | CHOP Research Institute
 

Retinoid Agonist Drug

1 - 1 of 1

CHOP Researchers Develop First Drug Treatment Approved for Severe Bone Disease

Published on
Jan 31, 2022
in Cornerstone Blog
CHOP Researchers Develop First Drug Treatment for FOP
Identified by CHOP researchers, palovarotene is the first drug approved (in Canada) for fibrodysplasia ossificans progressiva, a severe bone disease.
1 - 1 of 1